The global biopsy devices market size was estimated to be USD 2.27 billion in 2023 and is expected to reach at USD 5.20 billion by 2034 with a CAGR of 7.81% during the forecast period 2024-2034. Rising prevalence of cancer, increasing healthcare infrastructure, growing technological advancements in oncology, surge in adoption of minimally invasive surgical procedures, rising demand for disposable biopsy devices, increasing technologically advanced biopsy guidance systems such as vacuum-assisted guns, growing demand of cost-effective & advanced devices, and surge in launch of innovative platforms are some of the key factors boosting the market growth.
Surge in launch of innovative platforms is predicted to boost the market growth during the forecast period. Minimally invasive medical procedures have gained widespread popularity due to their numerous benefits. These procedures promote speedier patient recuperation and are less invasive. Data published by manufacturers indicate that minimally invasive surgeries are increasingly replacing invasive procedures and are associated with greater patient satisfaction. For instance, in July 2022, Medtronic has introduced a groundbreaking lung ablation procedure using the ILLUMISITE fluoroscopic navigation platform, which is the world's first of its kind. This minimally invasive approach allows precise navigation to reach even the most remote areas of the lung and enables comprehensive biopsy sampling in multiple directions.
By product, needle-based biopsy guns was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the growing need for these weapons to collect tissue samples from interior organs such the kidneys, breasts, & lungs' soft tissues, increasing need for painless and quick cell sample collection for biopsy, rising demand for vacuum-assisted devices, and surge in launch of advanced products. For instance, in August 2022, Mammotome DualCore Dual Stage Core Biopsy System is the latest product from Devicor Medical Products, Inc. Additionally, biopsy guidance systems is predicted to grow at fastest CAGR during the forecast period owing to the surge in preference for non-invasive procedures and increasing technological advancements.
By guidance technique, ultrasound-guided biopsy was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the rising adoption of this technique for cancer detection, increasing demand for minimally invasive procedures, growing demand for cost-effective & real-time imaging devices, and surge approval by regulatory bodies. For instance, in September 2023, Limaca Medical, known as Limaca, has received 510(k) clearance from the U.S. Food and Drug Administration for its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device. This approval comes after Limaca was granted FDA Breakthrough Device Designation for its Precision GI. Additionally, CT- guided biopsy is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of technologically advanced devices, increasing research & development activities for the manufacturing of advanced devices.
By application, breast biopsy was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the growing prevalence of breast cancer, increasing awareness regarding the disease, and rising launch of innovative systems. for instance, in August 2022, Mammotome, a subsidiary of Danaher Corporation, has introduced the Mammotome RevolveTM EX Dual Vacuum-Assisted Breast Biopsy System. This is the initial vacuum-assisted biopsy tool intended exclusively for removing benign breast lesions, and it operates twice as swiftly as traditional vacuum-assisted breast biopsy systems. This minimally invasive device enables physicians to offer improved care to patients with benign lesions, avoiding the hazards and invasiveness of open surgery while minimizing scarring. Additionally, is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of colorectal cancer, growing demand for minimally invasive procedure, increasing research & development activities, and surge in launch of novel therapies.
By end-user, ambulatory surgery center was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the accessibility and variety of medical treatments offered by ASCs, and rising preference for ASC for biopsy procedures by patients. Additionally, hospitals is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of advanced diagnostic tools, surge in number of skilled professionals capable of performing a wide range of biopsy types, increasing prevalence of diseases requiring biopsies, and growing mergers & acquisitions within market players. For instance, in March 2022, Triviton Healthcare, a worldwide medical technology firm, has completed the acquisition of The Kennedy Company, a prominent producer of X-ray shielding materials for radiation protection and acoustic barrier products. This strategic move positions Triviton to expand its services to the clients of the acquired company, particularly in the U.S., in the field of Breast Biopsy products.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for technologically advanced devices such as vacuum-assisted biopsy systems, rising prevalence of cancer, growing demand for disposable devices, and surge in launch of novel products. For instance, in June 2023, Argon Medical Devices has unveiled the SuperCore Advantage Semi-Automatic Biopsy Instrument, expanding its soft tissue biopsy product range within the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of cancer, growing technological advancements, and rising launch of new products. For instance, in August 2022, Actorius Innovations and Research Pvt Ltd (AIR) has introduced its inaugural product, the 'OncoDiscover Liquid Biopsy Test.' This minimally invasive test can be conducted multiple times and necessitates a blood sample of just 1.5ml.
Surge in launch of innovative platforms is predicted to boost the market growth during the forecast period. Minimally invasive medical procedures have gained widespread popularity due to their numerous benefits. These procedures promote speedier patient recuperation and are less invasive. Data published by manufacturers indicate that minimally invasive surgeries are increasingly replacing invasive procedures and are associated with greater patient satisfaction. For instance, in July 2022, Medtronic has introduced a groundbreaking lung ablation procedure using the ILLUMISITE fluoroscopic navigation platform, which is the world's first of its kind. This minimally invasive approach allows precise navigation to reach even the most remote areas of the lung and enables comprehensive biopsy sampling in multiple directions.
By product, needle-based biopsy guns was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the growing need for these weapons to collect tissue samples from interior organs such the kidneys, breasts, & lungs' soft tissues, increasing need for painless and quick cell sample collection for biopsy, rising demand for vacuum-assisted devices, and surge in launch of advanced products. For instance, in August 2022, Mammotome DualCore Dual Stage Core Biopsy System is the latest product from Devicor Medical Products, Inc. Additionally, biopsy guidance systems is predicted to grow at fastest CAGR during the forecast period owing to the surge in preference for non-invasive procedures and increasing technological advancements.
By guidance technique, ultrasound-guided biopsy was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the rising adoption of this technique for cancer detection, increasing demand for minimally invasive procedures, growing demand for cost-effective & real-time imaging devices, and surge approval by regulatory bodies. For instance, in September 2023, Limaca Medical, known as Limaca, has received 510(k) clearance from the U.S. Food and Drug Administration for its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device. This approval comes after Limaca was granted FDA Breakthrough Device Designation for its Precision GI. Additionally, CT- guided biopsy is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of technologically advanced devices, increasing research & development activities for the manufacturing of advanced devices.
By application, breast biopsy was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the growing prevalence of breast cancer, increasing awareness regarding the disease, and rising launch of innovative systems. for instance, in August 2022, Mammotome, a subsidiary of Danaher Corporation, has introduced the Mammotome RevolveTM EX Dual Vacuum-Assisted Breast Biopsy System. This is the initial vacuum-assisted biopsy tool intended exclusively for removing benign breast lesions, and it operates twice as swiftly as traditional vacuum-assisted breast biopsy systems. This minimally invasive device enables physicians to offer improved care to patients with benign lesions, avoiding the hazards and invasiveness of open surgery while minimizing scarring. Additionally, is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of colorectal cancer, growing demand for minimally invasive procedure, increasing research & development activities, and surge in launch of novel therapies.
By end-user, ambulatory surgery center was the highest revenue-grossing segment in the global biopsy devices market in 2023 owing to the accessibility and variety of medical treatments offered by ASCs, and rising preference for ASC for biopsy procedures by patients. Additionally, hospitals is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of advanced diagnostic tools, surge in number of skilled professionals capable of performing a wide range of biopsy types, increasing prevalence of diseases requiring biopsies, and growing mergers & acquisitions within market players. For instance, in March 2022, Triviton Healthcare, a worldwide medical technology firm, has completed the acquisition of The Kennedy Company, a prominent producer of X-ray shielding materials for radiation protection and acoustic barrier products. This strategic move positions Triviton to expand its services to the clients of the acquired company, particularly in the U.S., in the field of Breast Biopsy products.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for technologically advanced devices such as vacuum-assisted biopsy systems, rising prevalence of cancer, growing demand for disposable devices, and surge in launch of novel products. For instance, in June 2023, Argon Medical Devices has unveiled the SuperCore Advantage Semi-Automatic Biopsy Instrument, expanding its soft tissue biopsy product range within the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of cancer, growing technological advancements, and rising launch of new products. For instance, in August 2022, Actorius Innovations and Research Pvt Ltd (AIR) has introduced its inaugural product, the 'OncoDiscover Liquid Biopsy Test.' This minimally invasive test can be conducted multiple times and necessitates a blood sample of just 1.5ml.
Segmentation: Biopsy Devices Market Report 2022 - 2033
Biopsy Devices Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Needle-based Biopsy Guns
- Fine Needle Aspiration Biopsy (FNAB) Devices
- Core Needle Biopsy (CNB) Devices
- Vacuum-assisted Biopsy (VAB) Devices
- Biopsy Guidance Systems
- Robotic
- Manual
- Biopsy Needles
- Reusable
- Disposable
- Biopsy Forceps
- Hot Biopsy Forceps
- General Biopsy Forceps
- Others
- Punches
- Curettes
- Brushes
Biopsy Devices Market Analysis & Forecast by Guidance Technique 2023 - 2034 (Revenue USD Bn)
- Stereotactic-Guided Biopsy
- Ultrasound-Guided Biopsy
- CT- Guided Biopsy
- MRI-Guided Biopsy
- Others
Biopsy Devices Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Lung Biopsy
- Prostate Biopsy
- Breast Biopsy
- Colorectal Biopsy
- Others
Biopsy Devices Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic & Imaging Centers
- Others
Biopsy Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biopsy Devices Market: Product Estimates & Trend Analysis
8. Biopsy Devices Market: Guidance Technique Estimates & Trend Analysis
9. Biopsy Devices Market: Application Estimates & Trend Analysis
10. Biopsy Devices Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Biopsy Devices Market
13. Europe Global Biopsy Devices Market
14. Asia Pacific Global Biopsy Devices Market
15. Latin America Global Biopsy Devices Market
16. MEA Global Biopsy Devices Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Cardinal Health Inc.
- Argon Medical Devices
- Hologic Inc.
- Cook Medical
- Danaher Corporation
- Boston Scientific
- CONMED Corporation
- Becton
- Dickinson and Company
- DTR Medical
- Gallini Srl
- INRAD Inc.
- TransMed7 LLC
- Devicor Medical Products Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.27 Billion |
| Forecasted Market Value ( USD | $ 5.2 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
